Allianz: UBS remains Neutral on stock after CMD
(CercleFinance.com) - UBS confirms its Neutral rating on the stock and leaves its target price unchanged at E300 after the insurance group's CMD.
We do not anticipate any significant changes in EPS/capital distribution compared with Allianz's new three-year plan, UBS says.
Allianz's credible EPS targets and growth in the retail P&C business are integral to the plan, but require a reassessment for a more constructive valuation. The neutral rating is reiterated, the broker adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
We do not anticipate any significant changes in EPS/capital distribution compared with Allianz's new three-year plan, UBS says.
Allianz's credible EPS targets and growth in the retail P&C business are integral to the plan, but require a reassessment for a more constructive valuation. The neutral rating is reiterated, the broker adds.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.